Evaluating a surrogate endpoint at three levels, with application to vaccine development.
about
Recent developments in clinical trial designs for HIV vaccine researchSurrogates of protection in repeated low-dose challenge experiments.Partial protection against 2009 pandemic influenza A (H1N1) of seasonal influenza vaccination and related regional factors: Updated systematic review and meta-analyses.Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeEvaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacyRelationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.Model-robust inference for continuous threshold regression models.Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroadsFold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Calibration weighted estimation of semiparametric transformation models for two-phase sampling.Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.Some extensions in continuous models for immunological correlates of protection.Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine RegimensIncorporating founder virus information in vaccine field trials.Augmented trial designs for evaluation of principal surrogates.Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.Transformation Model Choice in Nonlinear Regression Analysis of Fluorescence-based Serial Dilution AssaysPredictive models and correlates of protection for testing biodefence vaccines.The fundamental link between pneumococcal carriage and disease.Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review.Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.Comparing biomarkers as trial level general surrogates.Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.A threshold method for immunological correlates of protection.A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpointEvaluation and comparison of predictive individual-level general surrogates.Learning from clinical medicine to improve the use of surrogates in ecology
P2860
Q28083514-46B9449C-6774-4158-BEF0-82AE7815C653Q30371157-B6A3B902-8E4E-422F-817A-470D8005229BQ30371873-72ABF480-A4F9-403C-9F0F-F193F34E4C28Q30540217-521763B3-0290-4D96-9075-7C714F21D428Q30714941-EB2FEA58-8F8D-43AD-BCA9-441494BD6FE3Q33538308-4882F4A4-4BCB-4E2C-AA83-A29483D25628Q33699928-9600F162-4D81-44EB-97CD-1994CD8A7C3FQ33916408-5AC1109A-64F8-41CA-9336-9D90BF4354B6Q34430200-E8140FE7-83F4-4565-9A06-47F225647D62Q35328844-F5CB9D16-1C89-4A89-BB31-AE72D98320C3Q35862314-D2146761-00CC-4796-92A8-E8110B5803E2Q35878996-5712E834-9F91-47D9-BBEF-3C46A25B5DEEQ35886464-36EF421D-3942-4F07-A8E1-009C09734B7CQ36413788-FCD2E207-16BB-4C18-BDC3-863E5ADF28B4Q36509005-8EACF881-E91D-430B-9718-B60DD2797D9CQ37025729-4FBEE097-68EC-43E0-B774-7A3976517C34Q37130739-064F3D94-D228-4543-8847-878BA2981E7AQ37252803-7C8FCBBE-36DE-49B8-AA39-1CE6601B7C48Q37745002-28C6D1A8-1F5B-44AA-94CD-B9A7FC778345Q38036689-FAD99CD8-A0DD-474F-9D33-0C5BA6B25264Q38590481-947E7378-44ED-4489-A080-119F6C9852A2Q38796580-DBFCA8EC-CE69-4045-AA1F-37AB71E8435BQ38852557-B171C7C2-D60F-4F23-A976-B579989A4906Q39869593-B43785F5-FB83-4EED-A1B3-AAD5C16D4A08Q39906181-64F50BD8-7C9F-4F6B-8229-54C4FCF0343EQ40208932-FF596746-6E58-4A53-B380-0DC953E12782Q41812285-85C93E64-20BF-40B0-B41F-998355791288Q41992194-C0129A59-C1AA-47C5-BD73-F5D01032F05BQ57269513-3D145421-409E-488F-A4CE-1485168B9583
P2860
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@en
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@nl
type
label
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@en
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@nl
prefLabel
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@en
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@nl
P2093
P2860
P356
P1476
Evaluating a surrogate endpoint at three levels, with application to vaccine development.
@en
P2093
Peter B Gilbert
Steven G Self
P2860
P304
P356
10.1002/SIM.3122
P407
P577
2008-10-01T00:00:00Z